SCHEMBL3606974

SCHEMBL3606974

NCCCOc1ncccc1-c1ccnc(Nc2cccc(Cl)c2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 5/20 0.56
CSNK2A1 P68400 1/20 0.54
ABL1 P00519 4/20 0.54
BCR P11274 3/20 0.54
PRKCA P17252 2/20 0.54
PRKCD Q05655 2/20 0.54
PIK3CA P42336 2/20 0.48
PIK3CB P42338 2/20 0.48
PIK3CG P48736 2/20 0.48
CDK2 P24941 4/20 0.48
CDK4 P11802 2/20 0.48
MAPT P10636 2/20 0.48
NPC1 O15118 1/20 0.48
CCNT1 O60563 1/20 0.48
CDK1 P06493 1/20 0.48
CCNB1 P14635 1/20 0.48
XBP1 P17861 1/20 0.48
CCNA2 P20248 1/20 0.48
CCND1 P24385 1/20 0.48
CCNE1 P24864 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3613093 0.86 ABL1 (0.57) CAMK2DCSNK2A1ABL1BCRPRKCA
SCHEMBL3600305 0.84 ABL1 (0.50) CAMK2DCSNK2A1ABL1BCRPRKCA
SCHEMBL3610465 0.82 CAMK2D (0.60) CAMK2DCSNK2A1ABL1BCRPRKCA
SCHEMBL3603990 0.82 CAMK2D (0.60) CAMK2DCSNK2A1ABL1BCRPRKCA
SCHEMBL3612180 0.80 CAMK2D (0.69) CAMK2DCSNK2A1ABL1BCRPRKCA
SCHEMBL3599515 0.80 ABL1 (0.65) CAMK2DCSNK2A1ABL1BCRPRKCA
SCHEMBL3612888 0.78 ABL1 (0.62) CAMK2DCSNK2A1ABL1BCRPRKCA
SCHEMBL13503026 0.78 ABL1 (0.62) CAMK2DCSNK2A1ABL1BCRPRKCA
SCHEMBL3609179 0.78 CDK2 (0.64) CAMK2DCSNK2A1ABL1BCRPRKCA
SCHEMBL3601621 0.77 ABL1 (0.59) CAMK2DCSNK2A1ABL1BCRPRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed
US-20100048597-A1 Organic Compounds and Their Uses NOVARTIS AG 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048597-A1 Organic Compounds and Their Uses OAT, OTC, AOX1 CAMK2D 4474/4885CSNK2A1 4549/4885ABL1 3215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.